nach oben

Erschienen in:

01.12.2023 | News item

Larotrectinib labelling update on hepatotoxicity and drug interactions

Erschienen in: Reactions Weekly | Ausgabe 1/2023

Einloggen, um Zugang zu erhalten

Excerpt

The Dosage and Administration, Warnings and Precautions, Adverse Reactions, and Drug Interactions sections of the Canadian product monograph for Vitrakvi (larotrectinib) have been updated with the risks of hepatotoxicity and drug interaction involving moderate cytochrome P450 (CYP) 3A4 inducers, advises Health Canada in Health Product InfoWatch . …

Product monograph update - Vitrakvi (larotrectinib) Health Product InfoWatch : Nov 2023. Available from: URL: https://www.canada.ca/en/health-canada/services/drugs-health-products/medeffect-canada/health-product-infowatch/november-2023.html#a3.2

Titel: Larotrectinib labelling update on hepatotoxicity and drug interactions
Publikationsdatum: 01.12.2023
Verlag: Springer International Publishing
Erschienen in: Reactions Weekly / Ausgabe 1/2023
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI: https://doi.org/10.1007/s40278-023-51750-9

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2023

Secukinumab

Ferric-carboxymaltose

Corticosteroids/cyclophosphamide/severe acute respiratory syndrome coronavirus 2 mRNA vaccine

Multiple drugs

Gentamicin/vancomycin

Gadobutrol